Do not start by asking a manufacturer for a quotation.

Start by defining the problem you want the product to solve, who the intended consumer is, what category the product may fall into, what benefit you intend to communicate, and why the consumer would choose your product over existing alternatives.

Then we examine the opportunity, scientific rationale, regulatory pathway, formulation possibilities, format, manufacturing feasibility and commercial viability.

At AspKom, the first question is not “How do we manufacture this?” It is “Should this product be developed at all?”

That distinction can save considerably more money than negotiating a lower manufacturing price.

Yes.

We assess the idea against market need, consumer problem, competition, differentiation, scientific plausibility, regulatory feasibility, formulation feasibility, manufacturing requirements and commercial potential.

The outcome is not automatically “yes.” Sometimes the correct professional recommendation is:

Do not develop this product in its present form.

That is a useful result. Spending money on a bad product merely because someone was enthusiastic about it is an expensive form of optimism.

There is no universally “best” nutraceutical product.

A commercially attractive product depends on the intersection of:

Consumer Need × Market Gap × Evidence × Regulatory Feasibility × Product Feasibility × Differentiation × Economics

A category can be growing and still be a poor opportunity for a particular founder.

We therefore look for the right opportunity for the business, not simply the currently fashionable ingredient or format.

For most early-stage businesses, I would rather see a strong product architecture built around one validated hero product than five mediocre products launched simultaneously.

The question is not how many SKUs you can manufacture. It is how many products you can successfully position, explain, distribute, sell and obtain repeat purchase for.

Some categories are extremely crowded. That does not automatically mean there is no opportunity.

It means the burden of differentiation becomes higher.

A new brand cannot simply say, “We also have vitamin X.”

We ask who exactly the product is for, what problem or use case it addresses, what is materially different, whether that difference is scientifically meaningful, whether it is legally communicable, whether consumers will pay for it, and whether the differentiation can survive competitive imitation.

Demand should not be inferred from personal enthusiasm.

We examine search behaviour, consumer discussions, competitor products, pricing, reviews, complaints, unmet needs, category growth signals, distribution patterns and available market evidence.

The objective is to convert:

“I think people need this.”

into:

“There is evidence that a defined consumer segment has this problem and may pay for this solution.”

Yes. But a market gap is not simply a category where there are fewer competitors.

Sometimes a low-competition category has low demand.

We therefore distinguish between:

• Market Gap
• Consumer Gap
• Product Gap
• Price Gap
• Format Gap
• Evidence Gap
• Trust Gap
• Communication Gap

You can study it.

You should not confuse studying a successful product with having a strategy.

We analyse its ingredients, dosage, format, positioning, claims, pricing, reviews, complaints, consumer proposition and competitive environment.

Then we ask: What can we improve, substantiate, differentiate or reposition?

A novel idea may have a larger opportunity, but it can also introduce greater scientific, regulatory, manufacturing and consumer-education uncertainty.

We therefore investigate both opportunity upside and uncertainty downside.

Novelty is valuable only when it can survive the rest of the product-development system.

Differentiation can come from consumer/use case, formulation architecture, ingredient combination, ingredient form or standardisation, dosage logic, delivery format, sensory experience, convenience, evidence, quality specifications, packaging, positioning, or business model.

A different label colour is not necessarily differentiation.

Yes.

A formula should not be judged only by whether the ingredients are individually “good.”

We assess the architecture:

Ingredient → Form → Dose → Combination → Intended Use → Biological Rationale → Safety → Regulatory Route → Format → Stability → Sensory → Manufacturing → Cost → Claims

The output identifies what is strong, what is weak, what requires evidence and what should be changed before manufacturing.

Not always.

If the manufacturer’s formulation team has developed a specification that you trust and your commercial, scientific and regulatory requirements are already clearly defined, an additional consultant may add little value.

But if the manufacturer is simultaneously trying to sell you the formulation, manufacture it, determine the ingredients, determine the dosage and advise on claims, an independent product-development review can be useful.

The manufacturer is an execution partner. AspKom’s role is to help the client make the underlying product decisions independently.

You can. In fact, sometimes you should.

If your specification is already validated, your ingredients, dosage, format, target cost, regulatory route and quality requirements are defined, going directly to a capable manufacturer may be the most efficient route.

AspKom is most valuable when the specification itself is uncertain.

A formula is not merely a list of ingredients.

Formula architecture considers what is being used, why it is being used, in what form, at what level, in what combination, in which dosage form, for which consumer, for which intended use, under which regulatory pathway, with which manufacturing and stability constraints.

That is what turns an ingredient list into a product-development decision.

Yes, where the project scope and technical requirements support it.

But “proprietary” should not be used casually.

A proprietary formulation needs meaningful differentiation, documented formulation logic, appropriate specifications and clear ownership arrangements.

There is no universal best ingredient.

We evaluate identity, form, source, standardisation, evidence, dose, safety, compatibility, regulatory status, stability, supply reliability, cost and sensory impact.

The question should therefore be:

Which ingredient is most appropriate for this product architecture?

Not: “Which ingredient is trending?”

Potentially, but botanical products require disciplined evaluation.

We may need to examine botanical identity, plant part, preparation, extraction method, standardisation, marker compounds, contaminants, adulteration risk, supplier documentation and regulatory status.

“Herbal” does not mean “automatically simple.”

Not necessarily.

The form, extraction characteristics and standardisation can materially affect the technical and scientific interpretation of an ingredient.

For botanical products, we therefore want to know exactly what the material is rather than accepting a broad ingredient name.

Technically possible does not mean scientifically, commercially or regulatorily sensible.

More ingredients can create higher cost, larger serving size, sensory problems, compatibility problems, stability issues, regulatory complications and weaker product positioning.

I prefer a purpose-built formula over an ingredient shopping list.

Dose should be considered in relation to intended use, ingredient form, scientific evidence, applicable regulatory requirements, target consumer and product format.

It should not simply be copied from another product.

Higher is not automatically better.

It may affect safety, regulatory acceptability, cost, sensory characteristics, stability and suitability for the intended consumer.

The objective is not maximum dosage. It is appropriate dosage within the intended product architecture.

This is exactly where product classification, regulatory requirements, intended use and claims become important.

A food product cannot simply be positioned as a medicine because the founder wants a stronger marketing story.

If you are operating within food categories regulated by FSSAI, compliance is fundamental.

For health supplements and nutraceuticals, FSSAI has a specific regulatory framework. The exact pathway depends on the product.

No.

Claims need to be assessed against the applicable regulatory framework and supporting evidence.

Our approach is:

Desired Benefit → Evidence → Ingredient/Dose Relevance → Regulatory Assessment → Permissible Communication

A food product should not simply be marketed as treating or curing disease.

The distinction between food and drug positioning matters enormously.

I would still verify it.

The brand owner should understand the regulatory basis rather than outsourcing responsibility blindly.

Manufacturer advice can be useful. It should not replace independent product-level regulatory reasoning.

No.

Manufacturing capability and product compliance are related but not identical questions.

We need to examine the actual product, ingredients, category, formulation, claims, label, manufacturing route and applicable requirements.

Potentially, but it needs to be assessed against the Ayurveda Aahara framework.

Ayurveda Aahara has specific requirements relating to permitted products and ingredients, claims, labelling, safety and approval pathways.

No.

Classification matters.

A food product and an Ayurvedic drug operate under different regulatory frameworks and should not be treated as interchangeable simply because both use traditional ingredients.

Not in the manner permitted for a medicine.

The applicable Ayurveda Aahara requirements must be reviewed before product communication is developed.

You should not pay AspKom merely to reach a manufacturer.

If all you need is production of an already-defined product specification, go directly to a suitable manufacturer.

AspKom becomes valuable when you need independent answers to questions such as:

• What should I manufacture?
• What should the formula contain?
• Is the dose appropriate?
• Which format makes sense?
• Can I legally position it this way?
• What specifications should the manufacturer follow?
• How should I compare manufacturers?
• What could cause the product to fail?

That is the decision layer above manufacturing.

A capable contract manufacturer can provide formulation support, sampling, production, quality systems, documentation, packaging and other manufacturing services depending on its capabilities.

Their core economic role, however, is execution.

AspKom is designed to sit before and around the manufacturing decision.

Our role can include:

Opportunity → Product Strategy → Scientific Logic → Formula Architecture → Regulatory Route → Format → Prototype → Manufacturer Selection → Manufacturing Readiness → Quality → Claims → Commercial Readiness

It can be.

If you already have a validated product concept, formulation, regulatory pathway, manufacturing specifications, quality specifications and commercial strategy, you may not need AspKom.

The value of consulting should be judged against the cost of making the wrong decision.

When the project involves significant uncertainty around product concept, formulation, ingredient selection, dosage, format, regulatory classification, claims, manufacturing route, prototype performance, stability, differentiation or commercial feasibility.

The more unresolved decisions there are, the more valuable an independent decision architecture becomes.

Because a prototype is not simply a sample bottle.

A useful prototype should answer technical questions such as:

• Does the formula work in the intended format?
• Is the dose physically feasible?
• Is the taste acceptable?
• Does the product dissolve or disperse?
• Is the serving size practical?
• Are the ingredients compatible?
• Can it potentially be manufactured at scale?

The prototype is therefore a learning instrument, not merely a sample.

Possible causes include ingredient incompatibility, poor excipient selection, excessive serving size, poor solubility, unpleasant flavour, oxidation, moisture sensitivity, poor compression, poor flow, inadequate process parameters, stability problems or packaging interaction.

Prototype failure is useful if it reveals the problem before commercial production.

There is no scientifically honest universal number.

Some formulations may converge quickly. Others require multiple iterations.

The number depends on formulation complexity, format, sensory requirements, ingredient behaviour and problems identified during testing.

I prefer defining acceptance criteria and revision logic rather than promising an arbitrary number of samples.

There is no meaningful single number.

Cost depends on:

Formula + Ingredients + Dose + Format + Batch Size + Packaging + Testing + Compliance + Development + Manufacturing + Logistics + Marketing

Anyone giving you a precise total before understanding the product specification is making assumptions.

That depends on the technical scope.

A simple formulation adaptation and a genuinely differentiated formulation-development project are not the same service.

The scope may include formulation research, ingredient evaluation, dosage design, regulatory review, prototype development, sensory optimisation, technical documentation and manufacturer transfer.

There is no universal MOQ.

MOQ depends on dosage form, formulation, raw-material procurement, packaging, batch economics and manufacturer capability.

Often, yes, but feasibility depends on the product.

A pilot strategy should be evaluated against formulation complexity, manufacturing capability, packaging, MOQ and eventual scale-up.

We define what “good” means before accepting the material.

Depending on the ingredient, this can involve identity, purity, potency, standardisation, contaminants, microbiological parameters, heavy metals, pesticide residues, adulteration risk, supplier qualification and COA review.

A COA is useful evidence. It is not a magical certificate of universal truth.

Not necessarily.

A product-development quality system should consider supplier qualification, specification, testing requirements and batch-level controls appropriate to the ingredient and product.

Extremely.

A product that performs perfectly on Day 1 but degrades before its expiry date is not a successful product.

Stability therefore needs to influence:

Formula → Packaging → Storage → Shelf Life → Manufacturing → Release Specification

Possible reasons include raw-material variation, botanical variation, flavour-system variation, process variation, moisture, storage and ingredient interaction.

This is why quality should be designed into the product rather than inspected only after manufacturing.

They should inform each other.

The brand proposition should not promise something the product cannot substantiate.

Likewise, a scientifically elegant formulation without a clear consumer proposition may struggle commercially.

AspKom connects:

Consumer → Need → Product → Evidence → Claim → Brand → Market

Only where the statement is genuinely supportable and compliant with applicable requirements.

Evidence language must correspond to actual evidence.

Having one study on one ingredient does not automatically mean the finished product is “clinically proven.”

Such language requires careful scrutiny and, for food products, can cross regulatory boundaries.

The applicable claims framework must be evaluated before communication is developed.

We do not build a marketing claim first and search for justification later.

No.

Scientific quality and commercial success are different dimensions.

A product can be scientifically sound and still fail because of poor positioning, high price, weak differentiation, poor taste, wrong format, inadequate distribution, high CAC, weak trust, poor repeat purchase or inadequate consumer education.

We should work backwards from:

Consumer Value → Competitive Position → COGS → Packaging → Distribution → Channel Margin → Marketing → Returns/Logistics → Target Contribution

Manufacturing price alone does not determine product economics.

There is no universal answer.

Channel selection depends on product category, consumer, price, repeat cycle, education requirement, margins, logistics, trust, acquisition cost and distribution economics.

Do not immediately manufacture a large batch.

First conduct a structured formulation and product review.

We would examine:

Ingredients → Dose → Evidence → Regulatory → Format → Stability → Manufacturing → Cost → Claims

No.

Sensory failure is a formulation problem to investigate, not automatically a reason to abandon the concept.

However, if acceptable sensory performance requires compromising the scientific or commercial architecture, we reconsider the format or formula.

That is a product-development decision, not simply a purchasing problem.

We can investigate ingredient selection, ingredient form, dosage, serving size, format, packaging, batch size, supplier strategy, manufacturing process and target price.

The answer may be to reformulate, change format, change pack architecture or abandon the concept.